Role of Rituximab Therapy in Glomerulonephritis
Open Access
- 1 January 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 21 (1), 14-17
- https://doi.org/10.1681/asn.2008070786
Abstract
B cell depletion with the monoclonal antibody rituximab is attracting increasing attention in systemic lupus erythematosus, vasculitis, and primary glomerulonephritis. Existing, uncontrolled data report high response rates in patients with refractory disease. If supported by the results of ongoing randomized trials, then rituximab and related B cell–depleting or –modulating drugs are likely to become a component in the future management of these disorders. Their use may improve patient outcomes by permitting more complete disease control and reduced exposure to glucocorticoid and traditional immunosuppressive drugs. The toxicity and infective risk of B cell–targeted agents in renal disease needs to be determined as well as their optimal dosing in combination with conventional agents.Keywords
This publication has 32 references indexed in Scilit:
- ABO-Incompatible Kidney Transplantation Using Antigen-Specific Immunoadsorption and Rituximab: A 3-Year Follow-upTransplantation, 2008
- B cells and tertiary lymphoid organs in renal inflammationKidney International, 2008
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple SclerosisThe New England Journal of Medicine, 2008
- Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)Lupus, 2007
- B cell depletion therapy in autoimmune diseasesFrontiers in Bioscience-Landmark, 2007
- B Cells Drive Early T Cell Autoimmunity In Vivo prior to Dendritic Cell-Mediated Autoantigen PresentationThe Journal of Immunology, 2006
- B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesionsAnnals Of The Rheumatic Diseases, 2005
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisThe New England Journal of Medicine, 2004
- LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double‐blind, placebo‐controlled studyArthritis & Rheumatism, 2003
- T Cell Activation in Rheumatoid Synovium Is B Cell DependentThe Journal of Immunology, 2001